Erratum: Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease (Scientific Reports (2016) 5:14781 DOI: 10.1038/srep14781);Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Takahashi, Hiroto ^a   Xia, Peng ^a   Cui, Jiankun ^a   Talantova, Maria ^a,e   Bodhinathan, Karthik ^a   Li, Wenjun ^a   Holland, Emily A ^a,e   Tong, Gary ^a,f   Piña Crespo, Juan ^a   Zhang, Dongxian ^a   Nakanishi, Nobuki ^a,e   Larrick, James W ^b   McKercher, Scott R ^a,e   Nakamura, Tomohiro ^a,e   Wang, Yuqiang ^c   Lipton, Stuart A ^a,d,e  

^a BURNHAM INSTITUTE   (United States)

^b Panorama Research Inc   (United States)

^c JINAN UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SCINTILLON INSTITUTE   (United States)

^f LUNDBECK RESEARCH USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ANURA; APOPTOSIS; BRAIN ISCHEMIA; CEREBROVASCULAR DISORDERS; DRUG EFFECTS; LONG TERM POTENTIATION; MAZE TEST; MEMBRANE POTENTIAL; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SYNAPTIC TRANSMISSION;

ANIMALS; ANURA; APOPTOSIS; BRAIN ISCHEMIA; CEREBROVASCULAR DISORDERS; LONG-TERM POTENTIATION; MAZE LEARNING; MEMANTINE; MEMBRANE POTENTIALS; NITRIC OXIDE; OXIDATION-REDUCTION; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 84944809968     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20750     Document Type: Erratum

References (51)

1. Lo, E. H. 2013 Thomas Willis Award Lecture: Causation and collaboration for stroke research. Stroke 45, 305-308 (2014
2. Simon, R. P., Swan, J. H., Griffiths, T. & Meldrum, B. S. Blockade of N-methyl-D-Aspartate receptors may protect against ischemic damage in the brain. Science 226, 850-852 (1984
3. Chen, H. et al. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid. Redox. Signal. 14, 1505-1517 (2011
4. Dirnagl, U., Iadecola, C. & Moskowitz, M. A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391-397 (1999
5. Kemp, J. A. & McKernan, R. M. NMDA receptor pathways as drug targets. Nat. Neurosci. 5 Suppl, 1039-1042 (2002
6. Tymianski, M. Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat. Neurosci. 14, 1369-1373 (2011
7. Hardingham, G. E. & Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682-696 (2010
8. Parsons, M. P. & Raymond, L. A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82, 279-293 (2014
9. Rogawski, M. A. & Wenk, G. L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9, 275-308 (2003
10. Chen, H. S. & Lipton, S. A. Mechanism of memantine block of NMDA-Activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. 499 (Pt 1), 27-46 (1997
11. Lipton, S. A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5, 160-170 (2006
12. Lipton, S. A. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 8, 803-808 (2007
13. Xia, P., Chen, H. S., Zhang, D. & Lipton, S. A. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 30, 11246-11250 (2010
14. Chen, H. S. et al. Open-channel block of N-methyl-D-Aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12, 4427-4436 (1992
15. Erkinjuntti, T., Roman, G., Gauthier, S., Feldman, H. & Rockwood, K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35, 1010-1017 (2004
16. Orgogozo, J. M., Rigaud, A. S., Stoffler, A., Mobius, H. J. & Forette, F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33, 1834-1839 (2002
17. Shih, A. Y. et al. The smallest stroke: occlusion of one penetrating vessel leads to infarction and a cognitive deficit. Nat. Neurosci 16, 55-63 (2013
18. Talantova, M. et al. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. USA 110, E2518-2527 (2013
19. Wang, Y. et al. The pharmacology of aminoadamantane nitrates. Curr. Alzheimer Res. 3, 201-204 (2006
20. Choi, Y. B. et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci. 3, 15-21 (2000
21. Lipton, S. A. & Stamler, J. S. Actions of redox-related congeners of nitric oxide at the NMDA receptor. Neuropharmacology 33, 1229-1233 (1994
22. Takahashi, H. et al. Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif. Neuron 53, 53-64 (2007
23. Chen, H. S. & Lipton, S. A. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-Aspartate-gated channels. J. Pharmacol. Exp. Ther. 314, 961-971 (2005
24. Blanpied, T. A., Clarke, R. J. & Johnson, J. W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J. Neurosci. 25, 3312-3322 (2005
25. Silver, I. A. & Erecinska, M. Intracellular and extracellular changes of [Ca2+ ] in hypoxia and ischemia in rat brain in vivo. J. Gen. Physiol. 95, 837-866 (1990
26. Wollmuth, L. P., Kuner, T., Seeburg, P. H. & Sakmann, B. Differential contribution of the NR1- And NR2A-subunits to the selectivity filter of recombinant NMDA receptor channels. J. Physiol. 491 (Pt 3), 779-797 (1996
27. Lipton, S. A. et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364, 626-632 (1993
28. Lipton, S. A. et al. Cysteine regulation of protein function-As exemplified by NMDA-receptor modulation. Trends Neurosci. 25, 474-480 (2002
29. Blanpied, T. A., Boeckman, F. A., Aizenman, E. & Johnson, J. W. Trapping channel block of NMDA-Activated responses by amantadine and memantine. J. Neurophysiol. 77, 309-323 (1997
30. Choi, Y., Chen, H. V. & Lipton, S. A. Three pairs of cysteine residues mediate both redox and zn2+ modulation of the nmda receptor. J. Neurosci. 21, 392-400 (2001
31. Kotermanski, S. E., Wood, J. T. & Johnson, J. W. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J. Physiol. 587, 4589-4604 (2009
32. Chen, H. S. & Lipton, S. A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97, 1611-1626 (2006
33. Parsons, C. G., Stoffler, A. & Danysz, W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53, 699-723 (2007
34. Chen, H. S. et al. Neuroprotective concentrations of the N-methyl-D-Aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86, 1121-1132 (1998
35. Okamoto, S. et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 15, 1407-1413 (2009
36. Ikonomidou, C. et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283, 70-74 (1999
37. Olney, J. W. et al. Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol. 12, 488-498 (2002
38. Gu, Z. et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 25, 6401-6408 (2005
39. Gu, Z. et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186-1190 (2002
40. Wang, Y. F. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4, 228-231 (1998
41. Lipton, S. A. Turning down, but not off. Nature 428, 473 (2004
42. Ischiropoulos, H. et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298, 431-437 (1992
43. Leonard, J. P. & Kelso, S. R. Apparent desensitization of NMDA responses in Xenopus oocytes involves calcium-dependent chloride current. Neuron 4, 53-60 (1990
44. Vyklicky, L., Jr., Benveniste, M. & Mayer, M. L. Modulation of N-methyl-D-Aspartic acid receptor desensitization by glycine in mouse cultured hippocampal neurones. J. Physiol. 428, 313-331 (1990
45. Bekkers, J. M. & Stevens, C. F. Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture. Proc. Natl. Acad. Sci. USA 88, 7834-7838 (1991
46. Segal, M. M. Epileptiform activity in microcultures containing one excitatory hippocampal neuron. J. Neurophysiol. 65, 761-770 (1991
47. Segal, M. M. & Furshpan, E. J. Epileptiform activity in microcultures containing small numbers of hippocampal neurons. J. Neurophysiol. 64, 1390-1399 (1990
48. Jaffrey, S. R. & Snyder, S. H. The biotin switch method for the detection of S-nitrosylated proteins. Sci. STKE 2001, pl1 (2001
49. Uehara, T. et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441, 513-517 (2006
50. Bederson, J. B. et al. Evaluation of 2, 3, 5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17, 1304-1308 (1986
51. Mackensen, G. B. et al. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. J. Neurosci. 21, 4582-4592 (2001